インダカテロール (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "インダカテロール" in Japanese language version.

refsWebsite

Global rank Japanese rank

4^th place

24^th place

2^nd place

6^th place

low place

68^th place

425^th place

447^th place

1,043^rd place

low place

9,532^nd place

6,690^th place

394^th place

doi.org

Cazzola M, Matera MG, Lötvall J (July 2005). “Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease”. Expert Opin Investig Drugs 14 (7): 775–83. doi:10.1517/13543784.14.7.775. PMID 16022567.
Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A (May 2007). “Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma”. Eur. Respir. J. 29 (5): 871–8. doi:10.1183/09031936.00060006. PMID 17251236.
Feldman, G; Siler, T; Prasad, N; Jack, D; Piggott, S; Owen, R; Higgins, M; Kramer, B et al. (2010). “Efficacy and safety of indacaterol 150 mcg once-daily in COPD: a double-blind, randomised, 12-week study”. BMC pulmonary medicine 10: 11. doi:10.1186/1471-2466-10-11. PMC 2848004. PMID 20211002.
Dahl R Chung KF Buhl R and others (June 2010). “Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD”. Thorax（英語版） 65 (6): 473–9. doi:10.1136/thx.2009.125435. PMID 20522841.
R. Buhl L.J. Dunn C. Disdier and others (October 2011). “Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD”. European Respiratory Journal（英語版） 38 (4): 797–803. doi:10.1183/09031936.00191810. PMID 21622587.

"FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease" (Press release). U.S. Food and Drug Administration. 1 July 2011. 2011年7月2日閲覧。[1]

Cazzola M, Matera MG, Lötvall J (July 2005). “Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease”. Expert Opin Investig Drugs 14 (7): 775–83. doi:10.1517/13543784.14.7.775. PMID 16022567.
Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A (May 2007). “Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma”. Eur. Respir. J. 29 (5): 871–8. doi:10.1183/09031936.00060006. PMID 17251236.
Feldman, G; Siler, T; Prasad, N; Jack, D; Piggott, S; Owen, R; Higgins, M; Kramer, B et al. (2010). “Efficacy and safety of indacaterol 150 mcg once-daily in COPD: a double-blind, randomised, 12-week study”. BMC pulmonary medicine 10: 11. doi:10.1186/1471-2466-10-11. PMC 2848004. PMID 20211002.
Dahl R Chung KF Buhl R and others (June 2010). “Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD”. Thorax（英語版） 65 (6): 473–9. doi:10.1136/thx.2009.125435. PMID 20522841.
R. Buhl L.J. Dunn C. Disdier and others (October 2011). “Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD”. European Respiratory Journal（英語版） 38 (4): 797–803. doi:10.1183/09031936.00191810. PMID 21622587.

Dahl R Chung KF Buhl R and others (June 2010). “Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD”. Thorax（英語版） 65 (6): 473–9. doi:10.1136/thx.2009.125435. PMID 20522841.
R. Buhl L.J. Dunn C. Disdier and others (October 2011). “Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD”. European Respiratory Journal（英語版） 38 (4): 797–803. doi:10.1183/09031936.00191810. PMID 21622587.